1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Co Cardiol 1992; 20: 248–54.
2. Carrie BJ, Hilberman M, Schroeder JS, Myers BD. Albuminuria and the permselective properties of the glomerulus in cardiac failure. Kidney Int 1980; 17: 507–14.
3. Eiskjaer H, Bagger JP, Mogensen CE et al. Enhanced urinary excretion of albumin in congestive heart failure: effect of ACE-inhibition. Scand. J Clin Lab Invest 1992; 52: 193–9.
4. Berton G, Citro T, Cordiano R et al. Urinary albumin excretion increases during an acute myocardial infarct especially in patients who develop heart failure. G Ital Cardiol 1995; 25: 999–1009.
5. Albright R, Brensilver J, Cortell S. Proteinuria in congestive heart failure. Am J Nephrol 1983; 3: 272–5.
6. Bortolotto LA, Silva HB, Galvao LF et al. Proteinuria in patients with congestive heart failure. Role of arterial hypertension. Arq Bras Cardiol 1993; 60: 243–5.
7. Abraham WT, Schrier RW. Renal function in congestive heart failure. In: Greenberg A. (ed.) Primer on kidney diseases., 2nd ed. San-Diego: Academic Press; 1998; 183–7.
8. Hall WD. Abnormalities of kidney function as a cause and a consequence of cardiovascular disease. Am J Med Sci 1999; 317: 176–82.
9. Matsusaka I, Hymes J, Ischikawa I. Angiotensin in progressive renal diseases: theory and practice. J Am Soc Nephrol 1996; 7: 2025–43.
10. Wolf G. Angiotensin II: a pivotal factor in the progression of renal disease. Nephrol Dial Transplant 1999; 14 (Suppl. 1): 42–4.
11. Matsushima H, Yoshida H, Machiguchi T et al. Urinary albumin and TGF-β1 levels as renal damage indices in patients with congestive heart failure. Clin Exp Nephrol 2002; 6: 21–29.
12. Yoshida H, Yashiro M, Liang P et al. Mesangiolytic glomerulopathy in severe congestive heart failure. Kidney Int 1998; 53: 880–91.
13. Goldfarb M, Abassi Z, Rosen S. Compensated heart failure predisposes to outer medullary tubular injury: studies in rats. Kidney Int 2001; 60: 607–13.
14. Knight EL, Glynn RJ, McIntyre KM et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 1999; 138 (5 Pt. 1): 849–55.
15. Metra M, Nodari S, Parrinello G et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail 2008; 10 (2): 188–95.
16. Damman K, Navis G, Voors AA et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007; 13 (8): 599–608.
17. Butler J, Forman DE, Abraham WT et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147 (2): 331–8.
18. Cowie MR, Komajda M, Murray-Thomas T et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 2006; 27 (10): 1216–22.
19. Плетнев Д.Д. Болезни сердца М.–Л., 1936.
20. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106 (5B): 13S–24S.
21. Clive DM, Stoff JS. Renal syndromes, associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310: 563–72.
22. Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000; 129: 1423–30.
23. Dzau VJ, Packer M, Lilly LS et al. Prostaglandins in severe congestive heart failure. Relation to activation of renin-angiotensin system and hyponatremia. N Engl J Med 1984; 310: 347–52.
24. Heerdink ER, Leufkens HG, Herings RM et al. NSAIDs associated with increased risk in elderly patients taking diuretics. Arch Intern Med 1998; 158: 1108–12.
25. Weinberg MS, Quigg RJ, Salant DJ, Bernard DB. Anuric renal failure precipitated by indomethacin and triamterene. Nephron 1985; 40: 216–8.
26. Ducloux D, Jamali M, Chalopin JM. Chronic congestive heart failure associated with bilateral renal artery stenosis. Clin Nephrol 1997; 48: 54–5.
27. Gray BH, Olin JW, Childs MB et al. Clinical benefit of renal artery angioplasty with stenting for the control of the recurrent and refractory congestive heart failure. Vasc Med 2002; 7: 275–9.
28. de Silva R, Nikitin NP, Bahndari S et al. Atherosclerotic renovascular disease in chronic heart failure: should we intervene? Eur Heart J 2005; 26: 1596–609.
29. ОССН ВНОК. Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (второй пересмотр). Сердечн. недостат. 2005; 2 (36): 2–21.
30. Kidney Disease Outcome Quality Initiative. Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (Suppl. 2): S1–S246.
31. Svensson M, Gustafsson F, Galatius S et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004; 10 (4): 297–303.
32. The ESC Task Force. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26 (11): 1115–40.
33. Auchus RA. Aldo is back: recent advances and unresolved controversies in hyperaldosteronism. Curr Opin Nephrol Hypertens 2003; 12: 153–8.
34. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–17.
35. Rossi J, Bayram M, Udelson JE et al. mprovement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care 2007; 9 (2): 82–6.
36. Beukhof CM, Hoorn EJ, Lindemans J, Zietse R. Novel risk factors for hospital-acquired hyponatraemia: a matched case-control study. Clin Endocrinol (Oxf) 2007; 66 (3): 367–72.
37. Bissram M, Scott FD, Liu L, Rosner MH. Risk factors for symptomatic hyponatraemia: the role of pre-existing asymptomatic hyponatraemia. Int Med J 2007; 37 (3): 149–55
38. Gill G, Huda B, Boyd A et al. Characteristics and mortality of severe hyponatraemia - a hospital-based study. Clin Endocrinol (Oxf) 2006; 65 (2): 246–9.
39. Chow KM, Szeto CC, Wong TY et al. Risk factors for thiazide-induced hyponatraemia. Q.J.M. 2003; 96 (12): 911–7.
40. Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant 2006; 21 (1): 70–6.
41. Szatalowitz VL, Arnbold PE, Chaimpovitz C et al. Radio immunoassay of plasma arginine vasopressin in hyponatriemic patients with congestive heart failure. N Engl J Med 1981; 305: 263–6.
42. Kalra PR, Anker SD, Coats AJS. Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovasc Res 2001; 51: 495–509.
43. Carmichael MC, Kumar R. Molecular biology of vasopressin receptors. Semin Nephrol 1994; 14: 341–8.
44. Nielsen S, Chou CL, Marples D et al. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA 1995; 92: 1013–7.
45. Teris J, Ecelbarger CA, Nilesen S, Knepper MA. Long-term regulation of four renal aquaporins in rat. Am J Physiol 1996; 271: F414–F422.
46. Nielsen S, Kwon T-W, Monster B et al. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10: 647–63.
47. Kwon TH, Hager H, Nejsum LN et al. Physiology and pathophysiology of renal aquaporins. Semin Nephrol 2001; 21: 231–8.
48. Knepper MA. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Physiol 1997; 272: F3–F12.
49. Deen PM, Verdjik MA, Knoers NV. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 1994; 264: 92–5.
50. Martin PY. Recent advances in the understanding of water metabolism in heart failure (involvement of aquaporin). Kidney Blood Press Res 2000; 23: 193–4.
51. Xu D, Yin X, Hui H et al. Urinary excretion of aquaporin-2 water channel protein in chronic heart failure rats. Chin Med J 2001; 114: 899–901.
52. Wong NL, Tsui JK. Upregulation of vasopressin V2 and aquaporin 2 in the inner medullary collecting duct of cardiomyopathic hamsters is attenuated by enalapril treatment. Metabolism 2002; 51: 970–5.
53. Ohnishi A, Orita Y, Takagi N et al. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J Pharmacol Exp Ther 1995; 272: 546–51.
54. Inoue T, Ohnishi A, Matsuo A et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998; 63: 561–70.
55. Gros P, Palm C. The treatment of hyponatraemia using vasopressin antagonists. Exp Physiol 2000; 85S: 7S–18S.
56. Yatsu T, Tomura Y, Tahara A et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 1999; 376: 239–46.
57. Martin P-Y, Abraham WT, Lieming X et al. Selective V2-receptor vasopressin antagonist decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 1999; 10: 2165–70.
58. Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355 (20): 2099–112.
59. Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107 (21): 2690–6.
60. Ghali JK, Koren MJ, Taylor JR et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006; 91 (6): 2145–52.
61. Моисеев С.В., Фомин В.В. Нефрологические аспекты хронической сердечной недостаточности. Тер. арх. 2003; 6: 72–6.
62. Greenberg A. Diuretic complications. Am J Med Sci 2000; 319: 10–24.
63. Waller PC, Ramsay LE. Predicting acute gout in diuretic-treated hypertensive patients. J Hum Hypertens 1989; 3: 457–61.
64. Spieker LE, Ruschitzka FT, Luscher TF, Noll G. The management of hyperuricemia and gout in patients with heart failure. Eur J Heart Failure 2002; 4: 403–10.
65. Naafs MA, van der Hoek C, van Duin S et al. Decreased renal clearance of digoxin in chronic congestive heart failure. Eur J Clin Pharmacol 1985; 28: 249–52.
66. Kittleson M, Hurwitz S, Shah MR et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol 2003; 41 (11): 2029–35.
67. Hui KK, Duchin KL, Kripalani K et al. Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther 1991; 49: 457–67.
68. Sica DA, Cutler RE, Parmer RJ et al. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic hepatic and renal insufficiency. Clin Pharmacokinet 1991; 20: 420–7.
69. Vetter W. Treatment of senile hypertension. The Fosinopril in Old Patiets Study (FOPS). Am J Hypertens 1997; 10: 255S–61S.
70. Карпов Ю.А., Мареев В.Ю., Чазова И.Е. Российские программы оценки эффективности лечения фозиноприлом больных с артериальной гипертонией и сердечной недостаточностью. Проект Три Ф (ФЛАГ, ФАСОН, ФАГОТ). Сердечн. недостат. 2003; 4 (5): 2–6.

Н.А.Мухин, В.В.Фомин,
С.В.Моисеев, М.С.Хамхоева